UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 118,428 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 5.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,259,178 shares of the company's stock after purchasing an additional 118,428 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.58% of Recursion Pharmaceuticals worth $15,272,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in the stock. Barclays PLC increased its stake in shares of Recursion Pharmaceuticals by 53.9% during the 3rd quarter. Barclays PLC now owns 697,432 shares of the company's stock valued at $4,596,000 after acquiring an additional 244,278 shares during the last quarter. Brighton Jones LLC boosted its holdings in shares of Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after acquiring an additional 6,699 shares during the period. Exchange Traded Concepts LLC raised its stake in shares of Recursion Pharmaceuticals by 101.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 50,761 shares of the company's stock valued at $343,000 after purchasing an additional 25,579 shares in the last quarter. KBC Group NV raised its stake in shares of Recursion Pharmaceuticals by 61.9% during the fourth quarter. KBC Group NV now owns 12,307 shares of the company's stock valued at $83,000 after purchasing an additional 4,705 shares in the last quarter. Finally, Institute for Wealth Management LLC. bought a new position in Recursion Pharmaceuticals during the 4th quarter valued at $3,928,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Trading Up 4.7%

NASDAQ:RXRX traded up $0.20 on Monday, hitting $4.38. 14,481,399 shares of the stock were exchanged, compared to its average volume of 13,711,290. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2.85 and a beta of 0.99. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company's 50-day moving average price is $4.91 and its 200 day moving average price is $6.40.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the firm posted ($0.39) EPS. The company's revenue was up 7.2% on a year-over-year basis. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have issued reports on the company. Morgan Stanley cut their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Leerink Partners reduced their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. Finally, Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and a consensus price target of $7.60.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.